• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Alkyl polyglycoside, a highly promising adjuvant in intranasal split influenza vaccines

tetano

Editor, Senior Moderator
Hum Vaccin Immunother. 2017 Jan 27:0. doi: 10.1080/21645515.2016.1278098. [Epub ahead of print]
[h=1]Alkyl polyglycoside, a highly promising adjuvant in intranasal split influenza vaccines.[/h] Wu H[SUP]1[/SUP], Bao Y[SUP]1[/SUP], Wang X[SUP]2[/SUP], Zhou D[SUP]2[/SUP], Wu W[SUP]1[/SUP].
[h=3]Author information[/h]

[h=3]Abstract[/h] Influenza viral infections are significant global public health concerns due to the morbidity and mortality associated with acute respiratory disease, secondary complications, and pandemic threats; thus, continuous efforts have been made to develop potent influenza vaccines. In this study, three different mucosal adjuvants-alkyl polyglycoside (APG), gellan gum, and chitosan (CS)-were evaluated for their efficacy in intranasal A/H1N1 or B split influenza vaccines administered to BALB/c mice. Protective immunity was monitored by serum analysis for IgG, hemagglutination inhibition (HI), and neutralizing antibody levels, as well as mucosal IgA levels in nasal and pulmonary lavage fluids. Survival, body weight, lung viral titer, and pulmonary immunopathology were also examined following lethal influenza challenge. Notably, all adjuvants amplified the IgG and IgA immune responses (not detected in immunization of influenza B) and increased survival rate compared to controls administered adjuvant-free intranasal vaccines. Alternatively, intramuscular immunization stimulated IgG production, but had no effect on IgA levels. Our collective analysis identified that APG was the most effective intranasal adjuvant, as all mice survived influenza challenge with limited body weight loss, viral titer, and pulmonary pathology, similar to those observed with intramuscular vaccination. This evidence supports that APG can elicit both systemic and mucosal immunity, and may be an effective adjuvant in intranasal split influenza A/H1N1 and B vaccines.


[h=4]KEYWORDS:[/h] Split influenza vaccine; alkyl polyglycoside; chitosan; gellan gum; intranasal immunization

PMID: 28129034 DOI: 10.1080/21645515.2016.1278098
[PubMed - as supplied by publisher]
 
Back
Top Bottom